Summary

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics

Description

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual bioinformatics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide.

Bioinformatics Partnering Terms and Agreements includes:

Trends in bioinformatics dealmaking in the biopharma industry since 2007
Analysis of bioinformatics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life bioinformatics deals
Access to over 1,500 bioinformatics deal documents
The leading bioinformatics deals by value since 2007
Most active bioinformatics dealmakers since 2007
The leading bioinformatics partnering resources
In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise bioinformatics rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of bioinformatics deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of bioinformatics agreements with numerous real life case studies
Comprehensive access to over 1500 actual bioinformatics contracts entered into by the world’s biopharma companies
Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a bioinformatics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary
 
 Chapter 1 – Introduction
 
 Chapter 2 – Trends in bioinformatics dealmaking
 
 2.1. Introduction
 2.2. Bioinformatics partnering over the years
 2.3. Bigpharma bioinformatics dealmaking activity
 2.4. Bigpharma not active in bioinformatics partnering
 2.5. Bioinformatics partnering by deal type
 2.6. Bioinformatics partnering by stage of development
 2.7. Bioinformatics partnering by disease type
 2.8. Average deal terms for bioinformatics partnering
 2.8.1 Bioinformatics partnering headline values
 2.7.2 Bioinformatics deal upfront payments
 2.7.3 Bioinformatic deal milestone payments
 2.7.4 Bioinformatic royalty rates
 
 Chapter 3 – Leading bioinformatics deals
 
 3.1. Introduction
 3.2. Top bioinformatic deals by value
 3.3. Top bioinformatics deals involving bigpharma
 
 Chapter 4 – Bigpharma bioinformatics deals
 
 4.1. Introduction
 4.2. How to use bigpharma bioinformatics partnering deals
 4.3. Bigpharma bioinformatics partnering company profiles
 Abbott
 Actavis
 Alcon Labs
 Allergan
 Amgen
 Apotex
 Astellas
 AstraZeneca
 Baxter International
 Bayer
 Biogen Idec
 Boehringer Ingelheim
 Bristol-Myers Squibb
 Celgene
 Cephalon
 Chugai
 CSL
 Daiichi Sankyo
 Dainnipon Sumitomo
 Eisai
 Eli Lilly
 Forest Laboratories
 Genzyme
 Gilead Sciences
 GlaxoSmithKline
 Hospira
 Johnson & Johnson
 Kyowa Hakko Kirin
 Lundbeck
 Menarini
 Merck & Co
 Merck KGaA
 Mitsubishi-Tanabe
 Mylan
 Novartis
 Novo Nordisk
 Nycomed
 Otsuka
 Pfizer
 Roche
 Sanofi
 Servier
 Shionogi
 Shire
 Stada
 Takeda
 Teva
 UCB
 Warner Chilcott
 Watson
 
 Chapter 5 – Bioinformatics dealmaking directory
 
 5.1. Introduction
 5.2. Company A-Z
 5.3. By stage of development
 Discovery
 Preclinical
 Phase I
 Phase II
 Phase III
 Regulatory
 Formulation
 Marketed
 5.4. By deal type
 Asset purchase
 Bigpharma outlicensing
 Co-development
 Collaborative R&D
 Co-market
 Contract service
 Co-promotion
 CRADA
 Cross-licensing
 Development
 Distribution
 Equity purchase
 Evaluation
 Grant
 Joint venture
 Licensing
 Litigation
 Loan
 Manufacturing
 Manufacturing - OEM
 Marketing
 Option
 Promotion
 Research
 Settlement
 Spin out
 Sub-license
 Supply
 Cardiovascular
 Central Nervous System
 Cosmetics
 Dental
 Dermatology
 Gastrointestinal
 Genetic disorders
 Genitourinary
 Hematology
 Hormonal
 Hospital care
 Immunology
 Infectives
 Inflammatory
 Metabolic
 Musculoskeletal
 Oncology
 Ophthalmics
 Respiratory
 Sensory organs
 
 Chapter 6 – Partnering resource center
 
 6.1. Online partnering
 6.2. Partnering events
 6.3. Further reading on dealmaking
 
 Appendices
 
 Appendix 1 – Deal type definitions
 Appendix 2 – Example bioinformatics partnering agreement
 
 About Wildwood Ventures
 Current Partnering
 Current Agreements
 Recent report titles from CurrentPartnering
 Order Form – Reports
 
 Table of figures
 
 Figure 1: Bioinformatics partnering since 2007
 Figure 2: Bigpharma – top 50 – bioinformatics deals 2007 to 2011
 Figure 3: Inactive bigpharma in bioinformatics partnering 2007-2011
 Figure 4: Bioinformatics partnering by deal type since 2007
 Figure 5: Bioinformatics partnering by deal type since 2007
 Figure 6: Bioinformatics partnering by disease type since 2007
 Figure 7: Bioinformatics partnering by oncology target since 2007
 Figure 8: Bioinformatics deals with a headline value – by stage of development
 Figure 9: Bioinformatics deal headline value distribution – discovery stage, US$million
 Figure 10: Bioinformatic deal headline value distribution – discovery stage, US$million - detail
 Figure 11: Bioinformatic deals with upfront payment values – by stage of development
 Figure 12: Bioinformatic deal upfront payment distribution – discovery stage, US$million
 Figure 13: Bioinformatic deal upfront payment distribution – discovery stage, US$million - detail
 Figure 14: Bioinformatic deals with milestone payments
 Figure 15: Bioinformatic deal milestone payment distribution, US$million
 Figure 16: Bioinformatic deals with royalty rates
 Figure 17: Top bioinformatics deals by value since 2007
 Figure 18: Top bioinformatics deals signed by bigpharma value since 2007
 Figure 19: Online partnering resources
 Figure 20: Forthcoming partnering events
 Figure 21: Deal type definitions
 Figure 22: Bioinformatics partnering agreement between Amgen and IBM, October 2008